BMS 986165

Drug Profile

BMS 986165

Alternative Names: BMS-986165

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antipsoriatics
  • Mechanism of Action Interferon type I inhibitors; Interleukin 12 inhibitors; Interleukin 23 inhibitors; PTK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I Autoimmune disorders; Psoriasis
  • Preclinical Inflammatory bowel diseases; Systemic lupus erythematosus

Most Recent Events

  • 07 Feb 2017 Phase-I clinical trials in Autoimmune disorders (In volunteers) in USA (PO) (NCT03044873)
  • 01 Jan 2017 Phase-I clinical trials in Psoriasis (In volunteers) in USA (PO) (NCT03004768)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical study in Inflammatory bowel disease and Systemic lupus erythematosus presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top